FierceBiotech14h
JPM25, Day 2: Pharma should 'run towards' vaccine efficacy conversations, says GSK CEO
Welcome to Day 2 of the J.P. Morgan Healthcare Conference 2025 in San Francisco. | Welcome to Day 2 of the J.P. Morgan ...
FierceBiotech14h
JPM25: Dexcom predicts 2025 growth, with Stelo pushing portfolio updates
After spending the past year extending its portfolio of continuous glucose monitors to include people who may not have ...
FierceBiotech19h
RegenXBio sells Hunter syndrome gene therapy's U.S., Asia commercial rights for $110M upfront
With an FDA approval submission for RegenXBio’s Hunter syndrome gene therapy already underway, the biopharma has now ...
FierceBiotech16h
Umoja secures $100M series C to bring more CAR-Ts into the clinic
Umoja Biopharma has secured $100 million in series C funds as the cancer-focused biotech looks to bring more of its cell ...
FierceBiotech17h
Sling's oral Tepezza rival hits goal in thyroid eye disease, setting stage for confirmatory phase 3
Sling Therapeutics’ oral challenger to Amgen’s intravenous Tepezza has hit the mark in a phase 2b/3 thyroid eye disease (TED) ...
FierceBiotech9h
Daiichi Sankyo gins up antibody research project with German research institute
Daiichi Sankyo is turning to the German city of Heidelberg for help developing antibodies. The Japanese pharma giant is ...
FierceBiotech12h
N-Power links up with Synapse to add oncologists to clinical research network
N-Power Medicine, a tech firm with a clinical trial platform for capturing real-world patient data, has acquired precision medicine firm Synapse Holdings. | N-Power Medicine, a tech firm with a ...